Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lundbeck Partners with Takeda in the US, Opts for Royalties, Focuses on Rexulti
Details : Lundbeck will cease all promotional efforts for Trintellix (vortioxetine hbr) with Takeda in the U.S. fully reallocate resources to other growth opportunities and accelerate growth for these products.
Product Name : Trintellix
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has given tentatively approved ANDA, a therapeutically equivalent reference listed drug product for Vortioxetine-Generic (Vortioxetine), indicated for the treatment of major depressive disorder.
Product Name : Vortioxetine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2022
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries1 , including the US, EU, Canada and Australia.
Product Name : Vortidif
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a new real-world study, the ability of Trintellix/Brintellix® (vortioxetine) to improve functioning in family, social, and work life for people living with Major Depressive Disorder was assessed.
Product Name : Trintellix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2021
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Finds that Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder
Details : A new study shows that people living with Major Depressive Disorder (MDD) and comorbid Generalized Anxiety Disorder (GAD) benefit from treatment with vortioxetine as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).
Product Name : Trintellix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
